Alnylam Pharmaceuticals (ALNY) EBT (2009 - 2026)

Alnylam Pharmaceuticals has reported EBT for 18 years, with the latest figure at $221.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 9460.35% year-over-year to $221.7 million; the trailing twelve-month figure through Mar 2026 stood at $553.1 million (up 274.95% YoY), and the FY2025 full-year result was $323.2 million, up 185.63% from the prior year.
• EBT for Q1 2026 stood at $221.7 million, up from $86.3 million in the prior quarter.
• The five-year high for EBT was $280.6 million in Q3 2025, with the low at -$405.9 million in Q3 2022.
• Historically, EBT has averaged -$81.6 million across 5 years, with a median of -$108.7 million in 2024.
• Annual changes were most pronounced in 2025 — EBT tumbled 216.63% — and 2026, when it jumped 9460.35%.
• Alnylam Pharmaceuticals' EBT stood at -$207.0 million in 2022, then soared by 33.49% to -$137.7 million in 2023, then plunged by 40.87% to -$194.0 million in 2024, then jumped by 144.47% to $86.3 million in 2025, then soared by 156.96% to $221.7 million in 2026.
• The last three EBT figures came in at $221.7 million (Q1 2026), $86.3 million (Q4 2025), and $280.6 million (Q3 2025), per Business Quant data.